68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma - Trial NCT05902377
Access comprehensive clinical trial information for NCT05902377 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 46 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
Phase 2
Dec 01, 2021
Jul 01, 2023
Primary Outcome
Binary reading of focal lesions identified on 68Ga-NY104 PET/CT
Summary
This is a prospective, single-center study in patients with renal cell carcinoma. The goal is
 to determine the sensitivity and specificity of 68Ga-NY104 PET/CT in the detection of clear
 cell renal cell carcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05902377
Non-Device Trial